Implication of microRNAs in the cardiovascular system

Current Opinion in Pharmacology

Volumn 8, Issue 2, 2008, Pages 181-188

  Scalbert, Elizabeth ^a   Bril, Antoine ^a  

^a INSTITUT DE RECHERCHES SERVIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR; MICRORNA;

ANGIOGENESIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR SYSTEM; CELL GROWTH; DEVELOPMENTAL STAGE; ELECTRIC CONDUCTIVITY; GENE EXPRESSION; GENE SEQUENCE; GENETIC REGULATION; HEART ARRHYTHMIA; HEART DEVELOPMENT; HEART FAILURE; HEART FUNCTION; HEART MUSCLE CONTRACTILITY; HEART VENTRICLE HYPERTROPHY; HUMAN; HUMAN GENOME; MOLECULAR CLONING; MORPHOGENESIS; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ANIMALS; CARDIOVASCULAR DISEASES; CARDIOVASCULAR PHYSIOLOGY; CARDIOVASCULAR SYSTEM; DRUG DELIVERY SYSTEMS; GENE EXPRESSION REGULATION; HUMANS; MICRORNAS;

EID: 40649116894     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2007.12.013     Document Type: Review

References (40)

1. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116 (2004) 281-297
2. Mack G.S. MicroRNA gets down to business. Nat Biotech 25 (2007) 631-638. In this study, MicroRNA development discussed from an industrial point of view.
3. Wang Y., Stricker H.M., Gou D., and Liu L. MicroRNAs: past and present. Front Biosci 12 (2007) 2316-2329
4. Wightman B., Ha I., and Ruvkun G. Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell 75 (1993) 855-862
5. Lee R.C., Feinbaum R.L., and Ambros V. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 75 (1993) 843-854
6. Lagos-Quintana M., Rauhut R., Yalcin A., Meyer J., Lendeckel W., and Tuschl T. Identification of tissue-specific microRNAs from mouse. Curr Biol 12 (2002) 735-739
7. Wienholds E., Kloosterman W.P., Miska E., Alvarez-Saavedra E., Berezikov E., De Bruijn E., Horvitz H.R., Kauppinen S., and Plasterk R.H. MicroRNA expression in zebrafish embryonic development. Science 309 (2005) 310-311
8. Cheng Y., Ji R., Yue J., Yang J., Liu X., Chen H., Dean D.B., and Zhang C. MicroRNAs are aberrantly expressed in hypertrophic heart, do they play a role in cardiac hypertrophy?. Am J Pathol 170 (2007) 1831-1839
9. Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., Mills A.A., Elledge S.J., Anderson K.V., and Hannon G.J. Dicer is essential for mouse development. Nat Genet 35 (2003) 215-217
10. Zhao Y., Ransom J.F., Li A., Vedantham V., Von Drehle M., Muth A.N., Tsuchihashi T., McManus M.T., Schwartz R.J., and Srivastava D. Dysregulation of cardiogenesis, cardiac conduction, and cell cycle in mice lacking miRNA-1-2. Cell 129 (2007) 1-15. This study revealed that miRNA biogenesis in the mouse heart is essential for cardiogenesis. Targeted deletion of miR-1-2 identified numerous miR1-related functions in the heart, including regulation of cardiac morphogenesis, electrical conduction, and cell-cycle control.
11. Giraldez A.J., Cinalli R.M., Glasner M.E., Enright A.J., Thomson J.M., Baskerville S., Hammond S.M., Bartel D.P., and Schier A.F. MicroRNAs regulate brain morphogenesis in zebrafish. Science 308 (2005) 833-838
12. Zhao Y., Samal E., and Srivastava D. Serum response factor regulates a muscle-specific microRNA that targets Hand2 during cardiogenesis. Nature 436 (2005) 214-220. This is the first study to report a major role for miR-1 in heart morphogenesis, controlling the balance between differentiation and proliferation of cardiac progenitor cells.
13. Srivastava S. Making or breaking the heart: from lineage determination to morphogenesis. Cell 126 (2006) 1037-1048
14. Van Rooij E., and Olson E.N. MicroRNAs: powerful new regulators of heart disease and provocative therapeutic targets. J Clin Invest 117 (2007) 2369-2376
15. Van Rooij E., Sutherland L.B., Liu N., Williams A.H., McAnally J., Gerard R.D., Richardson J.A., and Olson E.N. A signature pattern of stress-responsive microRNAs that can evoke cardiac hypertrophy and heart failure. Proc Natl Acad Sci U S A 103 (2006) 18255-18260. This study was the first to describe a signature pattern of miRNAs in both experimental and human cardiac hypertrophy and failure. It shows in vitro as well as in vivo using murine transgenic models, that overexpression of a particular single miRNA can induce pathological cardiac growth and failure.
16. Ikeda S, Won Kong S, Lu J, Bisping E, Zhang H, Allen PD, Golub TR, Pieske B, Pu WT: Altered microRNA expression in human heart disease. Physiol Genomics 2007, 31:367-373.
17. Van Rooij E., Sutherland L.B., Qi X., Richardson J.A., Hill J., and Olson E.N. Control of stress-dependent cardiac growth and gene expression by a microRNA. Science 316 (2007) 575-579. This study reports that the muscle-specific miR-208 controls expression of β-MHC gene, a regulator of cardiac contractility, introducing for the first time another possible functional role of miRNAs in cardiac contractility.
18. Sayed D., Hong C., Chen I.Y., Lypowy J., and Abdellatif M. MicroRNAs play an essential role in the development of cardiac hypertrophy. Circ Res 100 (2007) 416-424
19. Caré A., Catalucci D., Felicetti F., Bonci D., Addario A., Gallo P., Bang M.L., Segnalini P., Gu Y., Dalton N.D., et al. MicroRNA-133 controls cardiac hypertrophy. Nat Med 13 (2007) 613-618. This study indicates a key role for miR-133 in the regulation of cardiac hypertrophy. The in vivo demonstration was carried out using osmotic minipump subcutaneous infusion of an oligonucleotide 'antagomir' suppressing miR-133 expression. Modulation of miRNA expression, using oligonucleotide administration, may have future therapeutic application in the clinical setting.
20. Ahuja P., Sdek P., and MacLellan W.R. Cardiac myocyte cell cycle control in development, disease, and regeneration. Physiol Rev 87 (2007) 521-544
21. Xu C., Lu Y., Pan Z., Chu W., Luo X., Lin H., Xiao J., Shan H., Wang Z., and Yang B. The muscle-specific microRNAs miR-1 and miR-133 produce opposing effects on apoptosis by targeting HSP60, HSP70 and caspase-9 in cardiomyocytes. J Cell Sci 120 (2007) 3045-3052
22. Tatsuguchi M., Seok H.Y., Callis T.E., Thomson J.M., Chen J.F., Newman M., Rojas M., Hammond S.M., and Wang D.Z. Expression of microRNAs is dynamically regulated during cardiomyocyte hypertrophy. J Mol Cell Cardiol 42 (2007) 1137-1141
23. Thum T., Galuppo P., Wolf C., Fiedler J., Kneitz S., Van Laake L.W., Doevendans P.A., Mummery C.L., Borlak J., Haverich A., et al. MicroRNAs in the human heart. A clue to fetal gene reprogramming in heart failure. Circulation 116 (2007) 258-267. This study discovered for the first time a highly concordant miRNA expression pattern in fetal and failing human cardiac tissue. It supports a novel mode of regulation, miRNA-dependent for the cardiac transcriptome alterations observed in human heart failure.
24. Yang B., Lin H., Xiao J., Lu Y., Luo X., Li B., Zhang Y., Xu C., Bai Y., Wang H., et al. The muscle-specific microRNA miR-1 regulates cardiac arrhythmogenic potential by targeting GJA1 and KCNJ2. Nat Med 13 (2007) 486-491. This study describes a major role for miR-1 in electrical remodeling and arrhythmias. This constitutes an exciting step in the dissection of new molecular signaling pathways for arrhythmias and sudden death.
25. Xiao J., Luo X., Lin H., Zhang Y., Lu Y., Wang N., Zhang Y., Yang B., and Wang Z. MicroRNA miR-133 represses HERG K+ channel expression contributing to QT prolongation in diabetic hearts. J Biol Chem 282 (2007) 1236312367
26. Zhang Y., Xiao J., Lin H., Luo X., Wang H., Bai Y., Wang J., Zhang H., Yang B., and Wang Z. Ionic mechanisms underlying abnormal QT prolongation and the associated arrhythmias in diabetic rabbits: a role of rapid delayed rectifier K+ current. Cell Physiol Biochem 19 (2007) 225-238
27. Xiao J., Yang B., Lin H., Lu Y., Luo X., and Wang Z. Novel approaches for gene-specific interference via manipulating actions of microRNAs: examination on the pacemaker channel genes HCN2 and HCN4. J Cell Physiol 212 (2007) 285-292. This study is the first to grapple with the problem concerning the lack of gene-specificity of miRNA actions. Using the example of HCN2 and HCN4 isoforms targeted by miR-1 and miR-133. It demonstrates the feasibility of interfering with miRNA action in a gene-specific fashion.
28. Yang W.J., Yang D.D., Na S., Sandusky G.E., Zhang Q., and Zhao G. Dicer is required for embryonic angiogenesis during mouse development. J Biol Chem 280 (2005) 9330-9335
29. Poliseno L., Tuccoli A., Mariani L., Evangelista M., Citti L., Woods K., Mercatanti A., Hammond S., and Rainaldi G. MicroRNAs modulate the angiogenic properties of HUVECs. Blood 108 (2006) 3068-3071. This is the first study reporting miRNA expression profile in endothelial cells and their regulatory role in the angiogenic process.
30. Suarez Y., Fernandez-Hernando C., Pober J.S., and Sessa W.C. Dicer dependent microRNAs regulate gene expression and functions in human endothelial cells. Circ Res 100 (2007) 1164-1173
31. Kuehbacher A., Urbich C., Zeiher A.M., and Dimmeler S. Role of Dicer and Drosha for endothelial microRNAs expression and angiogenesis. Circ Res 101 (2007) 59-68
32. Ji R., Cheng Y., Yue J., Yang J., Liu X., Chen H., Dean D.B., and Zhang C. MicroRNAs expression signature and antisense-mediated depletion reveal an essential role of microRNA in vascular neointimal lesion formation. Circ Res 100 (2007) 1579-1588. This study demonstrates for the first time that multiple miRNAs are aberrantly expressed in the vascular wall after experimental angioplasty. A major role is described for miR-21.
33. Higuchi S., Ohtsu H., Suzuki H., Shirai H., Frank G.D., and Eguchi S. Angiotensin II signal transduction through the AT1 receptor: novel insights into mechanisms and pathophysiology. Clin Sci 112 (2007) 417-428
34. Martin M.M., Lee E.J., Buckenberger J.A., Schmittgen T.D., and Elton T.S. MicroRNA-155 regulates human angiotensin II type 1 receptor expression in fibroblasts. J Biol Chem 281 (2006) 18277-18284
35. Martin M.M., Buckenberger J.A., Jiang J., Malana G.E., Nuovo G.J., Chotani M., Feldman D.S., Schmittgen T.D., and Elton T.S. The human angiotensin II type 1 receptor +1166 a/C polymorphism attenuates microRNA-155 binding. J Biol Chem 282 (2007) 24262-24269. This study introduces miR-155 as an interesting negative regulator of angiotensin II system activity. MiR-155 directly targets the AT1 receptor and is likely to be the missing link between the AT1 receptor +1166A/C polymorphism and cardiovascular disease susceptibility.
36. Bonnardeaux A., Davies E., Jeunemaitre X., Féry I., Charru A., Clauser E., Tiret L., Cambien F., Corvol P., and Soubrier F. AngiotensinII type 1 receptor gene polymorphisms in human essential hypertension. Hypertension 24 (1994) 63-69
37. Cameron V.A., Mocatta T.J., Pilbrow A.P., Frampton C.M., Troughton R.W., Richards A.M., and Winterbourn C.C. Angiotensin type-1 receptor A1166C gene polymorphism correlates with oxidative stress levels in human heart failure. Hypertension 47 (2006) 1155-1161
38. Sethupathy P., Borel C., Gagnebin M., Grant G.R., Deutsch S., Elton T.S., Hatzigeorgiou A.G., and Antonarakis S.E. Human microRNA-155 on chromosome 21 differentially interacts with its polymorphic target in the AGTR1 3′ untranslated region: a mechanism for functional single-nucleotide polymorphisms related to phenotypes. Am J Hum Genet 81 (2007) 405-413
39. Czech M.P. MicroRNAs as therapeutic targets. N Eng J Med 354 (2006) 1194-1195
40. Krützfeldt J., Rajewsky N., Braich R., Rajeev K.G., Tuschl T., Manoharan M., and Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438 (2005) 685-689. A pioneer study using in vivo intravenous administration in mice of miRNA antagonists, termed 'antagomirs'. Antagomirs are chemically modified, cholesterol-conjugated single-stranded RNA analogs complementary to miRNAs. They harbor various modifications for RNAse protection and pharmacologic properties such as enhanced tissue and cellular uptake.